Lili Zhou
415 Fengyang Rd
Shanghai, 200003, China
Shanghai, 200003, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Therapeutic approaches to hypertension: A selective perspective on emerging evidence.
Journal: Journal of translational internal medicine
Published: August 27, 2026
Zanubrutinib-based regimen as the salvage or bridging treatment of CART therapy in relapsed or refractory, non-germinal center B-cell-like diffuse large B-cell lymphoma: a retrospective multicenter cohort study.
Journal: Frontiers in immunology
Published: February 07, 2026
Comparison of efficacy and adverse effects of CD19/20 CART versus CD19 single-target CART in R/R DLBCL: a single-center retrospective study.
Journal: Frontiers in immunology
Published: February 25, 2025
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma.
Journal: Frontiers in immunology
Published: January 27, 2025
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Blood
Published: July 31, 2024
C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study.
Journal: American journal of hematology
Published: June 05, 2024
An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk.
Journal: Chinese medical journal
Published: May 27, 2024
Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
Journal: Frontiers in immunology
Published: December 08, 2020
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
Journal: Frontiers of medicine
Published: September 17, 2019
Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy.
Journal: Frontiers of medicine
Published: August 26, 2019
Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
Journal: Annals of hematology
Published: May 26, 2019
Last Updated: 09/26/2026